Robert Martell
Insider
First SEC filing: Jan. 24, 2023 · Latest: Jan. 24, 2023
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net: $0
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| June 10, 2025 | INDP | A | 12,500 | · | · | 12,500 Direct | · | Acquired | (price as of 2026-10-02) |
| June 6, 2024 | INDP | A | 12,500 | · | · | 12,500 Direct | · | Acquired | (price as of 2026-10-02) |
| Feb. 13, 2023 | INDP | A | 20,000 | · | · | 20,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 20, 2023 | CRIS | A | 350,000 | · | · | 350,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 29, 2022 | CRIS | A | 252,000 | · | · | 252,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 28, 2021 | CRIS | A | 126,000 | · | · | 126,000 Direct | · | Acquired | (price as of 2026-10-02) |
| March 2, 2020 | CRIS | A | 385,000 | · | · | 385,000 Direct | · | Acquired | (price as of 2026-10-02) |
| May 23, 2019 | CRIS | A | 386,996 | · | · | 386,996 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 23, 2019 | CRIS | S 10b5-1 | 5,500 | $1.07 | $5,885 | 23,027 Direct | -19.28% | Disposed | -99.8% (price as of 2026-10-02) |
| Jan. 23, 2019 | CRIS | F | 8,473 | $1.07 | $9,066 | 28,527 Direct | -22.90% | Disposed | -99.8% (price as of 2026-10-02) |
| June 1, 2018 | CRIS | A | 303,000 | · | · | 303,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 22, 2018 | CRIS | A | 185,000 | · | · | 185,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Feb. 28, 2017 | CRIS | A | 120,000 | · | · | 120,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 19, 2016 | CRIS | A | 50,000 | · | · | 50,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 26, 2015 | CRIS | A | 25,000 | · | · | 25,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 27, 2014 | CRIS | A | 25,000 | · | · | 25,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 17, 2013 | CRIS | A | 25,000 | · | · | 25,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 5, 2012 | CRIS | A | 50,000 | · | · | 25,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Sept. 14, 2011 | CRIS | A | 25,000 | · | · | 25,000 Direct | · | Acquired | (price as of 2026-10-02) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| June 10, 2025 | INDP | Stock Option (right to buy) | Common Stock | $0.33 | June 10, 2035 | 12,500 | Acquired |
| June 6, 2024 | INDP | Stock Option (right to buy) | Common Stock | $2.63 | June 6, 2034 | 12,500 | Acquired |
| Feb. 13, 2023 | INDP | Stock Option (Right to Buy) | Common Stock | $1.71 | Feb. 13, 2033 | 20,000 | Acquired |
| Jan. 20, 2023 | CRIS | Employee stock option (right to buy) | Common Stock | $0.70 | Jan. 19, 2033 | 350,000 | Acquired |
| Jan. 29, 2022 | CRIS | Employee stock option (right to buy) | Common stock | $3.09 | Jan. 28, 2032 | 252,000 | Acquired |
| Jan. 28, 2021 | CRIS | Employee stock option (right to buy) | Common stock | $9.14 | Jan. 27, 2031 | 126,000 | Acquired |
| March 2, 2020 | CRIS | Employee stock option (right to buy) | Common stock | $1.26 | March 1, 2030 | 385,000 | Acquired |
| May 23, 2019 | CRIS | Employee stock option (right to buy) | Common stock | $1.16 | Jan. 20, 2029 | 386,996 | Acquired |
| June 1, 2018 | CRIS | Employee stock option (right to buy) | Common stock | $2.49 | May 31, 2028 | 303,000 | Acquired |
| Feb. 28, 2017 | CRIS | Non-qualified stock option | Common Stock | $2.31 | Feb. 27, 2027 | 120,000 | Acquired |
| Jan. 19, 2016 | CRIS | Non-qualified stock option | Common stock | $1.76 | Jan. 19, 2026 | 50,000 | Acquired |
| Jan. 26, 2015 | CRIS | Non-qualified stock option (right to buy) | Common stock | $1.94 | Jan. 26, 2025 | 25,000 | Acquired |
| Jan. 27, 2014 | CRIS | Non-qualified stock option (right to buy) | Common stock | $2.94 | Jan. 27, 2024 | 25,000 | Acquired |
| Jan. 17, 2013 | CRIS | Non-qualified stock option (right to buy) | Common stock | $3.32 | Jan. 17, 2023 | 25,000 | Acquired |
| Jan. 5, 2012 | CRIS | Non-qualified stock option (right to buy) | Common stock | $4.52 | Jan. 5, 2022 | 50,000 | Acquired |
| Sept. 14, 2011 | CRIS | Non-qualified stock option (right to buy) | Common stock | $3.36 | Sept. 14, 2021 | 25,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2021 | $370,508 | · | · | · | $198,186 | · | $17,400 | $1,502,517 |
| 2020 | $366,091 | · | · | · | $261,954 | · | $11,401 | $961,345 |
| 2018 | $186,712 | · | · | · | $124,688 | · | · | $914,426 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.